Clinical development of variant-adapted BNT162b2 COVID-19 vaccines: the early Omicron era
Authors:
Open Access
- 7 July 2023
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 22 (1) , 650-661
Abstract
No abstract availableKeywords
Funding Information
- funded by BioNTech SE
This publication has 48 references indexed in Scilit:
- Clinical development and approval of COVID-19 vaccinesExpert Review of Vaccines, 2022
- Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational studyBMJ, 2022
- Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) VariantNew England Journal of Medicine, 2022
- SARS-CoV-2 vaccination washes away original antigenic sinTrends in Immunology, 2022
- Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human seraScience, 2022
- Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variantNature, 2022
- Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccinationCell, 2022
- Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern AfricaNature, 2022
- Relative Reproduction Number of SARS-CoV-2 Omicron (B.1.1.529) Compared with Delta Variant in South AfricaJournal of Clinical Medicine, 2021
- Omicron variant genome evolution and phylogeneticsJournal of Medical Virology, 2021